

Alicante, October 4th, 2024

COMMUNICATION – MARKET NOTICE - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16th, 2014, on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "FacePhi" or "the Company") hereby notifies the following:

Facephi and Nice & Green, the main shareholder of the Company, signed on October 1st, 2024, a new loan for € 2,000,000.

The terms and conditions of the loan are as follows:

- The maturity date of the loan is March 31st, 2025. The loan may be repaid in cash or capitalized. In the case of capitalization (i.e., conversion of the loan into shares of the Company), the parties will enter into a new agreement establishing the exchange ratio.
- The loan will bear annual interest at Euribor plus 2%, payable at maturity. In addition to the principal, the parties may agree that accrued interest will be capitalized and added to the principal balance.
- The loan has a loan origination fee of 7%.

Javier Mira, Chairman of the Board of Directors, declares: *"This new financing agreement is consistent with the decision announced on May 13th, 2024, not to pursue the issuance of additional convertible bonds in our association with Nice & Green, Facephi's main shareholder, in order to maintain a stable and homogeneous shareholding structure. By avoiding the use of convertible instruments that could dilute shareholder participation, we prioritize financing alternatives that do not affect the interests of existing shareholders, thus ensuring a productive and successful long-term relationship with all our stakeholders."*

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors